GOSS vs. SYRE, SPRY, OCUL, XNCR, ETNB, GYRE, AUPH, NTLA, MRVI, and ELVN
Should you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Ocular Therapeutix (OCUL), Xencor (XNCR), 89bio (ETNB), Gyre Therapeutics (GYRE), Aurinia Pharmaceuticals (AUPH), Intellia Therapeutics (NTLA), Maravai LifeSciences (MRVI), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry.
Gossamer Bio vs.
Spyre Therapeutics (NASDAQ:SYRE) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.
Gossamer Bio's return on equity of -127.28% beat Spyre Therapeutics' return on equity.
Gossamer Bio received 134 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 66.38% of users gave Gossamer Bio an outperform vote.
Spyre Therapeutics presently has a consensus price target of $54.83, suggesting a potential upside of 157.55%. Gossamer Bio has a consensus price target of $9.20, suggesting a potential upside of 557.14%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Spyre Therapeutics.
Gossamer Bio has higher revenue and earnings than Spyre Therapeutics. Gossamer Bio is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by company insiders. Comparatively, 5.0% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Spyre Therapeutics has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.
In the previous week, Spyre Therapeutics had 6 more articles in the media than Gossamer Bio. MarketBeat recorded 7 mentions for Spyre Therapeutics and 1 mentions for Gossamer Bio. Spyre Therapeutics' average media sentiment score of 0.61 beat Gossamer Bio's score of 0.00 indicating that Spyre Therapeutics is being referred to more favorably in the media.
Summary
Spyre Therapeutics beats Gossamer Bio on 10 of the 18 factors compared between the two stocks.
Get Gossamer Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gossamer Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GOSS) was last updated on 2/22/2025 by MarketBeat.com Staff
Free GOSS Stock Alerts